John Aballi Sells 11,430 Shares of Exagen (NASDAQ:XGN) Stock

Exagen Inc. (NASDAQ:XGN) CEO John Aballi sold 11,430 shares of Exagen stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $3.61, for a total value of $41,262.30. Following the sale, the chief executive officer directly owned 702,997 shares of the company’s stock, valued at approximately $2,537,819.17. This trade represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Exagen Price Performance

XGN opened at $3.80 on Friday. The company has a market capitalization of $86.11 million, a price-to-earnings ratio of -4.13 and a beta of 1.90. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 1.35. Exagen Inc. has a 12-month low of $2.67 and a 12-month high of $12.23. The business’s fifty day simple moving average is $4.69 and its 200-day simple moving average is $7.91.

Wall Street Analyst Weigh In

Several research firms have recently commented on XGN. BTIG Research reduced their price target on shares of Exagen from $15.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. TD Cowen cut their price objective on shares of Exagen from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday. B. Riley Financial restated a “buy” rating and set a $8.00 target price (down from $18.00) on shares of Exagen in a report on Friday, January 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exagen in a research report on Wednesday, January 21st. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.43.

Institutional Trading of Exagen

A number of institutional investors have recently made changes to their positions in XGN. Bridgeway Capital Management LLC increased its position in Exagen by 10.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company’s stock valued at $194,000 after buying an additional 2,600 shares in the last quarter. Calamos Advisors LLC boosted its holdings in Exagen by 3.5% in the third quarter. Calamos Advisors LLC now owns 78,090 shares of the company’s stock worth $858,000 after acquiring an additional 2,677 shares in the last quarter. Truvestments Capital LLC grew its stake in shares of Exagen by 109.5% during the fourth quarter. Truvestments Capital LLC now owns 6,169 shares of the company’s stock worth $38,000 after acquiring an additional 3,225 shares during the last quarter. State Street Corp increased its holdings in shares of Exagen by 6.9% during the fourth quarter. State Street Corp now owns 71,256 shares of the company’s stock valued at $433,000 after acquiring an additional 4,600 shares in the last quarter. Finally, Huntleigh Advisors Inc. increased its holdings in shares of Exagen by 6.3% during the third quarter. Huntleigh Advisors Inc. now owns 93,353 shares of the company’s stock valued at $1,026,000 after acquiring an additional 5,492 shares in the last quarter. Institutional investors and hedge funds own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.